The estimated Net Worth of Sean Mc Lennan is at least $41.1 mil dollars as of 16 June 2022. Mr Lennan owns over 30,000 units of Molecular Templates Inc stock worth over $41,100 and over the last 3 years he sold MTEM stock worth over $0.
Mr has made over 1 trades of the Molecular Templates Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of MTEM stock worth $24,600 on 16 June 2022.
The largest trade he's ever made was buying 30,000 units of Molecular Templates Inc stock on 16 June 2022 worth over $24,600. On average, Mr trades about 15,000 units every 0 days since 2022. As of 16 June 2022 he still owns at least 30,000 units of Molecular Templates Inc stock.
You can see the complete history of Mr Lennan stock trades at the bottom of the page.
Sean McLennan is the Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer at Molecular Templates Inc.
Mr McLennan is 50, he's been the Sr. VP of Fin., Controller, Interim Principal Accounting Officer y Interim CFO & Treasurer of Molecular Templates Inc since . There are 9 older and 10 younger executives at Molecular Templates Inc. The oldest executive at Molecular Templates Inc is David Hoffmann, 75, who is the Independent Director.
Sean's mailing address filed with the SEC is C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD., SUITE 100, AUSTIN, TX, 78729.
Over the last 7 years, insiders at Molecular Templates Inc have traded over $22,993,582 worth of Molecular Templates Inc stock and bought 14,744,530 units worth $82,519,716 . The most active insiders traders include Target N Vbb Biotech Ag Bio..., David Hirsch y Capital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of $532,718. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth $587,500.
molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.
Molecular Templates Inc executives and other stock owners filed with the SEC include: